Skip to main content
    B

    Boston Scientific Corp (BSX)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $44.16
    +1.15 (+2.69%)

    Market Cap: $62.32B

    Last updated: Oct 16, 2026 at 1:54 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    85%(33/39)
    Avg Surprise
    +17.24%
    Streak
    14 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.75
    Range$0.58 - $0.82
    23 analysts
    EPS RevisionsNo revisions (7d)
    0
    8
    30d
    EPS Estimate DriftChange to current
    90d ago$0.84-9.8%
    60d ago$0.81-6.4%
    30d ago$0.81-6.4%
    7d ago$0.77-1.5%
    Current$0.75
    Revenue Consensus
    $5.1B
    Range$4.7B - $5.3B
    23 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.89
    Range$0.78 - $1.00
    26 analysts
    Revenue Consensus
    $5.5B
    Range$5.2B - $5.9B
    26 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.89---
    Sep 26EST
    		-$0.75---
    Jun 26
    Reported Jul 29
    		$0.86$0.83+3.61%Beat+14.7%
    Mar 26
    Reported Apr 22
    		$0.80$0.79+1.27%Beat+6.7%
    Dec 25
    Reported Feb 4
    		$0.80$0.78+2.56%Beat+14.3%
    Sep 25
    Reported Oct 22
    		$0.75$0.71+5.63%Beat+19.0%
    Jun 25
    Reported Jul 23
    		$0.75$0.73+2.74%Beat+21.0%
    Mar 25
    Reported Apr 23
    		$0.75$0.67+11.94%Beat+33.9%
    Dec 24
    Reported Feb 5
    		$0.70$0.66+6.06%Beat+27.3%
    Sep 24
    Reported Oct 23
    		$0.63$0.59+6.78%Beat+26.0%
    Jun 24
    Reported Jul 24
    		$0.62$0.58+6.90%Beat+17.0%
    Mar 24
    Reported Apr 24
    		$0.56$0.51+9.80%Beat+19.1%
    Dec 23
    Reported Jan 31
    		$0.55$0.51+7.84%Beat+22.2%
    Sep 23
    Reported Oct 26
    		$0.50$0.48+4.17%Beat+16.3%
    Jun 23
    Reported Jul 27
    		$0.53$0.49+8.16%Beat+20.5%
    Mar 23
    Reported Apr 26
    		$0.47$0.43+9.30%Beat+20.5%
    Dec 22
    Reported Feb 1
    		$0.45$0.47-4.26%Miss+0.0%
    Sep 22
    Reported Oct 26
    		$0.43$0.44-2.27%Miss+4.9%
    Jun 22
    Reported Jul 27
    		$0.44$0.42+4.76%Beat+10.0%
    Mar 22
    Reported Apr 27
    		$0.39$0.39+0.00%Beat+5.4%
    Dec 21
    Reported Feb 2
    		$0.45$0.44+2.27%Beat+95.7%
    Sep 21
    Reported Oct 27
    		$0.41$0.40+2.50%Beat+10.8%
    Jun 21
    Reported Jul 27
    		$0.40$0.37+8.11%Beat+400.0%
    Mar 21
    Reported Apr 28
    		$0.37$0.31+19.35%Beat+32.1%
    Dec 20
    Reported Feb 3
    		$0.23$0.31-25.81%Miss-50.0%
    Sep 20
    Reported Oct 28
    		$0.37$0.25+48.00%Beat-5.1%
    Jun 20
    Reported Jul 29
    		$0.08$-0.02+500.00%Beat-79.5%
    Mar 20
    Reported Apr 29
    		$0.28$0.32-12.50%Miss-20.0%
    Dec 19
    Reported Feb 5
    		$0.46$0.44+4.55%Beat+17.9%
    Sep 19
    Reported Oct 23
    		$0.39$0.38+2.63%Beat+11.4%
    Jun 19
    Reported Jul 24
    		$0.39$0.38+2.63%Beat-4.9%
    Mar 19
    Reported Apr 24
    		$0.35$0.36-2.78%Miss+6.1%
    Dec 18
    Reported Feb 6
    		$0.39$0.36+8.33%Beat+14.7%
    Sep 18
    Reported Oct 24
    		$0.35$0.34+2.94%Beat+12.9%
    Jun 18
    Reported Jul 25
    		$0.41$0.34+20.59%Beat+28.1%
    Mar 18
    Reported Apr 25
    		$0.33$0.32+3.13%Beat+13.8%
    Dec 17
    Reported Feb 1
    		$0.34$0.34+0.00%Beat+13.3%
    Sep 17
    Reported Oct 26
    		$0.31$0.31+0.00%Beat-
    Jun 17
    Reported Jul 27
    		$0.32$0.31+3.23%Beat-
    Mar 17
    Reported Apr 27
    		$0.29$0.30-3.33%Miss-
    Dec 16
    Reported Feb 2
    		$0.30$0.29+3.45%Beat-

    Key Metrics

    Valuation
    P/E Ratio13.76EV/EBITDA13.62x
    Price/FCF17.91xFCF Yield5.58%
    Profitability
    Profit Margin17.50%Operating Margin22.90%
    ROE15.30%ROIC10.68%
    Financial Health
    Debt/Equity0.51xInterest Coverage11.63x
    Current Ratio1.24xQuick Ratio0.74x
    Trading Statistics
    Beta0.57Avg Volume18.76M
    52-Week High$105.6552-Week Low$41.39

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$42.78
    SMA 20$43.40
    SMA 50$46.18
    SMA 200$59.36
    EMA 10$43.23
    EMA 20$43.59
    EMA 50$45.13
    EMA 200$58.43

    MACD

    Line: -0.65Signal: -0.90Hist: 0.25

    ADX

    ADX: 17.6+DI: 21.4-DI: 18.9

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down80.0
    PSAR$41.65

    Bollinger Bands

    Upper Band$45.25
    Lower Band$41.54
    %B Position853%(Upper)
    Band Width0.70

    RSI (14-Day)

    Neutral
    51.2

    Momentum Oscillators

    Stoch %K62.9
    Stoch %D53.5
    Williams %R-9.0
    ROC (10d)2.1%
    Momentum0.93
    CCI (20d)63.4
    MFI (14d)33.9

    Volatility Measures

    ATR (14d)$1.28(2.9%)
    StdDev (20d)0.93
    Hist Vol22.4%(Moderate)

    Volume Flow

    VWAP$44.02
    OBV-516.6M
    AD Line-422.3M
    CMF (20d)0.101

    Volume Metrics

    Avg Vol (20d)17.6M
    Vol Ratio0.8x
    VWMA (20d)$43.43

    Pivot Points

    R3$44.92
    R2$44.25
    R1$43.63
    Pivot Point$42.95
    S1$42.33
    S2$41.65
    S3$41.03

    Advanced Oscillators

    TSI-14.93
    Ultimate Osc59.0
    KST-72.38

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$5.44B$5.20B$5.29B$5.07B$5.06B$4.66B$4.56B$4.21B$4.12B$3.86B$3.73B$3.53B
    Cost of Revenue$1.59B$1.59B$1.61B$1.52B$1.64B$1.45B$1.47B$1.31B$1.27B$1.21B$1.15B$1.10B
    Gross Profit$3.85B$3.61B$3.68B$3.54B$3.42B$3.21B$3.10B$2.90B$2.85B$2.65B$2.58B$2.43B
    Operating Expenses$2.67B$2.51B$2.85B$2.49B$2.60B$2.29B$2.42B$2.16B$2.33B$1.97B$2.00B$1.73B
    R&D$554.00M$516.00M$569.00M$514.00M$526.00M$443.00M$459.00M$407.00M$383.00M$366.00M$362.00M$356.00M
    SG&A$1.80B$1.78B$1.83B$1.74B$1.72B$1.60B$1.61B$1.56B$1.45B$1.36B$1.38B$1.24B
    Operating Income$1.18B$1.10B$825.00M$1.05B$819.00M$921.00M$675.00M$733.00M$520.00M$675.00M$584.00M$693.00M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$96.00M$90.00M$90.00M$87.00M$90.00M$82.00M$80.00M$79.00M$77.00M$69.00M$64.00M$66.00M
    Income Before Tax$1.06B$1.16B$700.00M$939.00M$941.00M$805.00M$585.00M$669.00M$420.00M$608.00M$505.00M$610.00M
    Income Tax Expense$155.00M$-176,000,000$31.00M$183.00M$146.00M$133.00M$23.00M$200.00M$98.00M$115.00M$1.00M$105.00M
    Net Income$905.00M$1.34B$670.00M$755.00M$795.00M$672.00M$563.00M$468.00M$322.00M$493.00M$504.00M$504.00M
    EBITDA$1.51B$1.60B$1.16B$1.38B$1.41B$1.29B$1.06B$1.05B$808.00M$981.00M$883.00M$978.00M
    EBIT$1.16B$1.25B$790.00M$1.02B$1.03B$887.00M$666.00M$747.00M$497.00M$677.00M$570.00M$675.00M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BSX

    Government Contracts

    Gov Obligations (TTM)
    $23.78M
    Gov Obligations / Revenue
    0.1%
    Obligations YoY
    -14.1%
    Active Awards
    1,471
    New Awards (TTM)
    1,409
    Avg Remaining Term
    8.5 mo

    Top agency: Department of Defense at 61.2% of trailing twelve month obligations across 3 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26126N0005Department of Veterans AffairsDepartment of Veterans Affairs$954240Oct 1, 2025
    36C26126F0019Department of Veterans AffairsDepartment of Veterans Affairs$821898Oct 1, 2025
    36C26226N0239Department of Veterans AffairsDepartment of Veterans Affairs$693000Jan 1, 2026
    36C25226N0450Department of Veterans AffairsDepartment of Veterans Affairs$607804Jul 15, 2026
    36C25026N0158Department of Veterans AffairsDepartment of Veterans Affairs$600601Nov 4, 2025
    W81K0025PA252Department of DefenseDepartment of the Army$552770Oct 1, 2025
    36C24626N0477Department of Veterans AffairsDepartment of Veterans Affairs$518712Feb 12, 2026
    36C25626N0278Department of Veterans AffairsDepartment of Veterans Affairs$518712Jan 1, 2026
    SPE2D626F4E8HDepartment of DefenseDefense Logistics Agency$445800Apr 23, 2026
    36C25226N0083Department of Veterans AffairsDepartment of Veterans Affairs$436810Oct 1, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and Ionis Pharmaceuticals (IONS)

    Analysts have issued bullish ratings for Boston Scientific (BSX) and Ionis Pharmaceuticals (IONS). Truist Financial maintained a Buy rating for Boston Scientific with a $51.00 price target...

    The Globe and Mail•10/15/26•Bullish

    Lobbying Update: $642,000 of BOSTON SCIENTIFIC CORPORATION lobbying was just disclosed

    Boston Scientific Corporation (BSX) disclosed $642,000 in lobbying expenditures for Q3 2026, covering a wide range of issues from medical device regulation and patient access to tax provisions and supply chain...

    Quiver Quantitative•10/15/26•Somewhat-Bullish

    Mesa Laboratories stock has results scheduled for November 9, 2026

    Mesa Laboratories (MLAB) is set to report its second-quarter fiscal year 2027 results and provide fiscal year 2027 guidance on November 9...

    ad-hoc-news.de•10/15/26•Neutral

    What Capital Group Global Growth ETF (CGGO) Bought: Boston Scientific Leads on Oct. 13

    On October 13, 2026, the Capital Group Global Growth Equity ETF (CGGO) saw net buying of $13.9 million. Boston Scientific (BSX) was the largest buy at $6.0 million...

    Yahoo Finance•10/15/26•Bullish

    Beckman Coulter Diagnostics Appoints Former Boston Scientific Executive Catherine Jennings as President

    Beckman Coulter Diagnostics, a Danaher Corporation subsidiary, has appointed Catherine "Cat" Jennings as President. Jennings, previously President of Vascular Therapies at Boston Scientific...

    citybiz•10/14/26•Somewhat-Bullish

    BSX Valuation and Fair Value

    P/E
    13.8x
    Forward P/E
    13.2x
    EV/EBITDA
    13.6x
    P/FCF
    17.9x
    PEG
    0.6x
    P/B
    2.6x
    See GNG's fair value

    BSX Profitability: Margins, ROIC and FCF

    Gross margin
    69.9%
    Operating margin
    22.9%
    Net margin
    17.5%
    ROIC
    10.7%
    ROE
    15.3%
    FCF margin
    17.3%
    FCF yield
    5.6%

    BSX Competitors

    CompanyTicker
    Cencora Inc.COR
    Takeda Pharmaceutical Co Ltd ADRTAK
    Cigna CorpCI
    Cardinal Health IncCAH
    Regeneron Pharmaceuticals IncREGN
    Natera IncNTRA
    Moderna IncMRNA
    Becton Dickinson and CompanyBDX

    Sector: Healthcare

    BSX Analyst Ratings

    Consensus
    Buy
    Analysts
    31
    Strong Buy
    8
    Buy
    17
    Hold
    6
    Sell
    0
    Strong Sell
    0

    BSX Bull Case vs Bear Case

    Bull case

    • BSX converts 17.3% of revenue into free cash flow.
    • BSX beat EPS estimates in 100.0% of its last 8 reported quarters.
    • 80.6% of BSX's analyst ratings are Buy or Strong Buy.

    BSX Earnings: Beat Rate and Next Report

    Beat rate
    8 of 8 quarters (100.0%)
    Average surprise
    5.1%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.75
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 8 down

    Frequently Asked Questions About BSX

    Does BSX pay dividends?

    Boston Scientific Corp (BSX) does not currently pay a regular dividend.

    What is BSX's P/E ratio?

    Boston Scientific Corp has a price-to-earnings (P/E) ratio of 13.76.

    What is BSX's market cap?

    Boston Scientific Corp (BSX) has a market capitalization of $62.32B with a current stock price of $44.16.

    Related stocks

    Sector: Healthcare

    All stocks starting with B

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In